Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorPT. Prodia Stem Cell Indonesia

About this trial

The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.

Eligibility criteria

Qualifiers

Visual field defects at the initial examination with Humphrey perimetry are between 25% to 50%

Willing to sign informed consent as research subjects

Willing to do the peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue

Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherent Tomography (OCT) examinations, electroretinogram examinations and fill out a quality of life questionnaire

Disqualifiers

Pregnant or nursing women

Positive result of HIV test

Have a history of eye tumours

In the immunosuppressive treatment or other drugs that can affect the growth of transplanted stem cells

Trial design

Treatments tested in this trial

  • Conditioned Medium (CM)
  • Umbilical Cord Mesenchymal Stem Cell (UC-MSC)

Treatment groups

18 Participants
are divided into 3 treatment groups

Sponsors and collaborators